You are now viewing 41 - 50 of 170 results
August 16, 2004 | Program Result Report
From 2000 to 2001, researchers at Boston University School of Public Health examined how the growth of direct-to-consumer advertising of prescription drugs affects the patient-provider relationship.
March 1, 2003 | Program Result Report
The Leapfrog Group developed standards for evaluating hospitals' use of computerized physician order entry systems, and devised and tested techniques to raise awareness about the importance of considering the presence of systems.
August 1, 2003 | Program Result Report
During 1999 and 2000, Brenda Motheral, PhD, and researchers at the University of Arizona Health Sciences Center examined the impact that a cap (or limit) on prescription drug benefits has on the drug-taking behavior of beneficiaries ages 65 or older who are enrolled in Medicare HMO plans.
December 1, 2003 | Program Result Report
During 2002 and 2003, the Neighborhood Health Clinic in Naples, Fla. created a new state-of-the-art Medication Room to improve the delivery of medications to its 12,000 clients.
January 1, 2001 | Program Result Report
During the 1980s, expenditures on pharmaceuticals nationwide increased by 152 percent. HMOs implemented a number of cost-control mechanisms to slow the rate of growth of pharmaceutical expenditures, and were successful in doing so compared to fee-for-service health plans.
March 6, 2008 | Program Result Report
Researchers at Brandeis University used data from two state-run prescription drug programs for low-income seniors to examine how differences in prescription drug coverage affect enrollment, drug use and spending in state programs.
July 31, 2008 | Program Result Report
Pharmacogenomics is the study of how inherited variations in genes dictate a person's reaction to a drug. Louis F. Rossiter, PhD, and other researchers examined how pharmacogenomics fits within the current health care market.
December 1, 2007 | Program Result Report
The Manhattan Institute for Policy Research released a white paper with recommendations on how to reform the pipeline for new medications, including the approval process by the Food and Drug Administration (FDA).
January 1, 1997 | Program Result Report
From 1992 to 1995, researchers at Harvard Medical School collected a comprehensive cross-section of data on state Medicaid pharmaceutical programs and various models of cost-containment. They also investigated the impacts of five cost-containment methods.
August 1, 2006 | Program Result Report
The Treatment Research Institute compared the therapeutic practices of office-based clinicians who treat patients with substance use disorders to those of clinicians in an outpatient program at a community clinic.